Cargando…
SARS-CoV-2 Related Myocarditis: What We Know So Far
A minority of patients with severe acute respiratory syndrome coronavirus 2 (COVID-19) develop cardiovascular complications, such as acute cardiac lesions with elevated troponins, de novo systolic heart failure, pericardial effusion and, rarely, acute myocarditis. The prevalence of COVID-19-related...
Autores principales: | Mistrulli, Raffaella, Ferrera, Armando, Muthukkattil, Melwyn Luis, Volpe, Massimo, Barbato, Emanuele, Battistoni, Allegra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380706/ https://www.ncbi.nlm.nih.gov/pubmed/37510815 http://dx.doi.org/10.3390/jcm12144700 |
Ejemplares similares
-
COVID-19 and Myocarditis: What Do We Know So Far?
por: Pirzada, Ashar, et al.
Publicado: (2020) -
What we know so far
Publicado: (2021) -
Anabaenopeptins: What We Know So Far
por: Monteiro, Patrick Romano, et al.
Publicado: (2021) -
Autoimmune pancreatitis: What we know so far
por: Masood, Muaaz
Publicado: (2021) -
Incremental Hemodialysis: What We Know so Far
por: Soi, Vivek, et al.
Publicado: (2022)